Al Altomari, President and Chief Executive Officer

Al Altomari is the President and Chief Executive Officer of Agile Therapeutics and a member of the Company’s Board of Directors. Prior to being named President and CEO, Al served as Agile’s Executive Chairman in which capacity he closed a $45 million venture round in May 2010. Al has more than 28 years of experience in the pharmaceutical industry, with more than 20 years focused on the development and marketing of specialty pharmaceutical products. Currently Al is leading Agile through the final stages of development and commercialization of contraceptive products using the Company’s proprietary transdermal technology.

Prior to joining Agile Therapeutics, Al served as Chief Executive Officer of Barrier Therapeutics and as a member of the Company’s Board of Directors. In 2008, Al  completed the successful sale of the Company  (NASDAQ: BTRX) to GSK/Stiefel Laboratories for a 73% premium. His initial role with the Company had been as Chief Commercial Officer, beginning in August 2003, and he was promoted to Chief Operating Officer in  February 2006. During his tenure at Barrier, Al set up Barrier’s commercial infrastructure, all sales and marketing activities for Barrier’s product portfolio and oversaw management of all worldwide business development initiatives.

Prior to joining Barrier, Al functioned in numerous executive roles in general management, commercial operations, business development, product launch preparation and finance within Johnson & Johnson from 1982 to 2003. He completed his tenure with Johnson & Johnson as General Manager of Ortho Neutrogena, where he successfully led the integration of Ortho Dermatological and Neutrogena Professional. Al also served as Vice President/Franchise Head of Ortho-McNeil Pharmaceutical’s Women’s Health Care Franchise where he introduced several life cycle and new product development initiatives, including the launch of ORTHO EVRAO™, a contraceptive patch. Sales of the Women’s Health Care Franchise were well in excess of $1 Billion.

Al currently serves as a member of the Board of Directors of Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), DUSA Pharmaceuticals Inc. (NASDAQ: DUSA) and Nitric Bio Therapeutics. In July 2007, Al was recognized by PharmaVoice Magazine as one of the Top 100 Most Inspirational and Influential Leaders in the Life Sciences Industry. He received a Masters in Business Administration from Rider University in Lawrenceville, New Jersey, and his Bachelor of Science degree from Drexel University in Philadelphia, Pennsylvania, with a dual major in finance and accounting. Al currently serves on the Le Bow College (Drexel’s Business School) advisory board.